| 3.41 -0.09 (-2.57%) | 07-28 14:41 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.25  |
1-year : | 4.63 |
| Resists | First : | 3.64 |
Second : | 3.97 |
| Pivot price | 3.66 |
|||
| Supports | First : | 3.11 |
Second : | 2.59 |
| MAs | MA(5) : | 3.53 |
MA(20) : | 3.6  |
| MA(100) : | 2.98 |
MA(250) : | 2.32 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 22.4 |
D(3) : | 31.9 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 8.47 | Low : | 1.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CYCN ] has closed above bottom band by 6.7%. Bollinger Bands are 54.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.6 - 3.62 | 3.62 - 3.64 |
| Low: | 3.36 - 3.39 | 3.39 - 3.41 |
| Close: | 3.46 - 3.5 | 3.5 - 3.53 |
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.
Mon, 27 Jul 2026
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Mon, 27 Jul 2026
Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Mon, 27 Jul 2026
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sat, 25 Jul 2026
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
Fri, 24 Jul 2026
CYCN|Cyclerion Therapeutics Inc|Price:3.440|Chg%:-0.060 - TradingKey
Fri, 24 Jul 2026
CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025 - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 22.7 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 48 (K) |
| EPS | -1.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.6 |
| Profit Margin | -264.8 % |
| Operating Margin | -337.5 % |
| Return on Assets (ttm) | -45.9 % |
| Return on Equity (ttm) | -67.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.07 |
| Sales Per Share | 0.45 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -2.61 |
| PEG Ratio | 0 |
| Price to Book value | 2.13 |
| Price to Sales | 7.41 |
| Price to Cash Flow | -4.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|